Kazia Therapeutics ROCE
¿Qué es el ROCE de Kazia Therapeutics?
El ROCE de Kazia Therapeutics Limited es 0.00%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en ASX en comparadas con Kazia Therapeutics
¿Qué hace Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Empresas con roce similar a Kazia Therapeutics
- Omega Alpha Spac tiene ROCE de -0.01%
- The Gap tiene ROCE de -0.01%
- Elemental Royalties Ltd tiene ROCE de -0.01%
- Auburn National Bancorp tiene ROCE de -0.01%
- Galaxy Digital tiene ROCE de -0.01%
- The Gap tiene ROCE de -0.01%
- Kazia Therapeutics tiene ROCE de 0.00%
- Tejon Ranch Co tiene ROCE de 0.01%
- Glen Burnie Bancorp tiene ROCE de 0.02%
- MSP Steel & Power tiene ROCE de 0.02%
- TTL Beteiligungs- und Grundbesitz-AG tiene ROCE de 0.03%
- First Foundation Inc tiene ROCE de 0.03%
- FirstMark Horizon Acquisition tiene ROCE de 0.03%